Want to join the conversation?
Steve Scala with Cowen asks about the upcoming KEYTRUDA PDUFA in head and neck cancer, should it be assumed approval will be only for third line PD-L1 positive patients. $MRK said in terms of approval, it cannot be commented what exactly the label will look like.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.